TIAA CREF Individual & Institutional Services LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 10.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 128,498 shares of the company’s stock after acquiring an additional 12,109 shares during the quarter. TIAA CREF Individual & Institutional Services LLC’s holdings in Merck & Co., Inc. were worth $18,672,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently added to or reduced their stakes in the company. Whittier Trust Co. raised its holdings in Merck & Co., Inc. by 1.8% in the 3rd quarter. Whittier Trust Co. now owns 602,983 shares of the company’s stock valued at $87,794,000 after acquiring an additional 10,512 shares during the last quarter. TIAA Trust National Association lifted its stake in shares of Merck & Co., Inc. by 75.1% during the 3rd quarter. TIAA Trust National Association now owns 7,558 shares of the company’s stock worth $1,098,000 after purchasing an additional 3,241 shares during the period. Patron Partners LLC lifted its stake in shares of Merck & Co., Inc. by 2.5% during the 3rd quarter. Patron Partners LLC now owns 9,904 shares of the company’s stock worth $1,439,000 after purchasing an additional 241 shares during the period. Mayflower Financial Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 10.6% during the third quarter. Mayflower Financial Advisors LLC now owns 22,309 shares of the company’s stock worth $3,242,000 after purchasing an additional 2,146 shares during the last quarter. Finally, Advisors Asset Management Inc. acquired a new stake in shares of Merck & Co., Inc. during the third quarter worth $48,704,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Merck & Co., Inc. Stock Performance
Merck & Co., Inc. stock opened at $133.56 on Friday. Merck & Co., Inc. has a 12-month low of $95.36 and a 12-month high of $156.92. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The company has a market capitalization of $329.26 billion, a price-to-earnings ratio of 137.69, a price-to-earnings-growth ratio of 6.62 and a beta of 0.13. The firm’s fifty day moving average price is $145.28 and its 200 day moving average price is $129.29.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.58 earnings per share. On average, research analysts forecast that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th will be given a $0.88 dividend. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.85. This represents a $3.52 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, December 15th. Merck & Co., Inc.’s dividend payout ratio is 350.52%.
Merck & Co., Inc. News Roundup
Investors following MRK have been watching these news items:
- Positive Sentiment: Merck partnered with Isomorphic Labs to discover small-molecule oncology drug candidates, combining the AI drug-design company’s approach with Merck’s data and drug-development expertise. The collaboration could support longer-term growth as Merck prepares for Keytruda’s eventual patent expiry. Business Wire: Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Neutral Sentiment: Zacks Research raised its rating on Merck from “strong sell” to “hold,” a modest improvement in analyst sentiment rather than a bullish endorsement. MarketBeat: Zacks Research stock recommendations
- Negative Sentiment: Merck has stopped development of nemtabrutinib and ended its Phase 3 BELLWAVE studies after concluding the drug’s benefit-risk profile did not justify continuing. This removes a late-stage blood-cancer candidate from its pipeline. Yahoo Finance: What Does Merck Losing Nemtabrutinib Mean For Its Blood Cancer Pipeline?
Analysts Set New Price Targets
A number of equities analysts have weighed in on MRK shares. DZ Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and set a $153.00 price target on the stock. in a research note on Tuesday, November 3rd. TD Cowen lifted their price target on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a “hold” rating in a report on Wednesday, September 23rd. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research note on Wednesday, August 12th. Freedom Broker upped their price objective on Merck & Co., Inc. from $125.00 to $140.00 and gave the stock a “hold” rating in a report on Monday, November 2nd. Finally, Royal Bank Of Canada dropped their price objective on Merck & Co., Inc. from $145.00 to $140.00 and set a “sector perform” rating for the company in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $155.74.
View Our Latest Research Report on Merck & Co., Inc.
Insiders Place Their Bets
In related news, EVP Richard Deluca sold 58,185 shares of the stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $148.01, for a total value of $8,611,961.85. Following the sale, the executive vice president owned 112,955 shares of the company’s stock, valued at $16,718,469.55. This trade represents a 34.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is owned by corporate insiders.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
